IPRx is Intelacia’s weekly briefing on pharmaceutical patent landscapes, drug exclusivity battles, biosimilar IP disputes, and regulatory intersections curated by experts with 14+ years in the innovation ecosystem.
Join IP professionals, pharma counsel, and patent strategists receiving curated pharma IP intelligence.
No spam · Unsubscribe anytime · Always free
Where AI-assisted inventorship is most vulnerable to challenge
How USPTO guidance is being interpreted in prosecution
What PTAB filings signal about future invalidity arguments
Which AI-generated compounds carry hidden disclosure risk
Every edition delivers actionable pharma IP intelligence curated by Intelacia's interdisciplinary team of engineers, scientists, and legal experts.
Track upcoming drug patent expirations, lifecycle management strategies, and market exclusivity timelines for blockbuster molecules.
Summaries of key PTAB decisions, Hatch-Waxman disputes, biosimilar litigations, and inter partes review outcomes.
Detailed coverage of biosimilar patent challenges, FDA Purple Book updates, and interchangeability patent landscapes.
Comparative analysis of pharma patent filings across USPTO, EPO, and emerging markets spotting strategic shifts early.
Deep-dives into Big Pharma and biotech IP portfolios who's building moats, who's vulnerable, and where the white spaces are.
Perspectives from Intelacia's team at the intersection of science, law, and strategy.
Major pharma companies including AstraZeneca, Sanofi, Pfizer, and Eli Lilly have active AI drug discovery partnerships. The IP implications are already landing in prosecution and M&A rooms.
Post-DABUS case law is still evolving globally. USPTO, EPO, and UKIPO are issuing new guidance quarterly. Counsel who aren't tracking this are already behind their counterparts.
With over $200B in branded drug revenues at risk from patent expiry this decade, exclusivity strategy has never mattered more, and AI-generated portfolios add a new layer of diligence complexity.